Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: A systematic critical review

Pharmacogenetics and Genomics

Volumn 21, Issue 7, 2011, Pages 357-364

  Estany Gestal, Ana ^a,b   Salgado Barreira, Angel ^a,c   Sánchez Diz, Paula ^a   Figueiras, Adolfo ^a,c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Santiago University Clinical Hospital   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

CYP2C9; CYP2C9*2; CYP2C9*3; gastrointestinal haemorrhage; nonsteroidal anti inflammatory drugs

Indexed keywords

CYTOCHROME P450 2C9; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL ASSESSMENT; DATA ANALYSIS; DISEASE ASSOCIATION; GASTROINTESTINAL HEMORRHAGE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MEDICAL RECORD; MEDLINE; METHODOLOGY; PRIORITY JOURNAL; PUBLISHING; REVIEW; RISK; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW;

EID: 79959808571     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328346d2bb     Document Type: Review

References (53)

1. Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, et al. Genome-wide association to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2008; 9:23-33.
2. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacological Sci 2001; 22:298-305. (Pubitemid 32523913)
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279:1200-1205. (Pubitemid 28193431)
4. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004; 329:15-19. (Pubitemid 38869995)
5. Martin MH, Codina C, Tuset M, Carné X, Nogué S, Ribas J. Drug related problems as a cause of hospital admission. Med Clin 2002; 118:205-210. (Pubitemid 34218204)
6. Spiegel BMR, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal anti-inflammatory drugs: cost effectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005; 53:185-197. (Pubitemid 40530158)
7. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician 2007; 76:1005-1012.
8. Laporte JR, Ibáñez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAID. Newer versus older agents. Drug Safety 2004; 27:411-420. (Pubitemid 38608459)
9. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340:1888-1899. (Pubitemid 29272670)
10. Singh G. Gastrointestinal complications of prescription and over-thecounter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Am J Ther 2000; 7:115-122.
11. Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343:834-839.
12. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther 2005; 77:1-16. (Pubitemid 40089477)
13. Xie H-G, Prasad HC, Kim RB. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54:1257-1270. (Pubitemid 35284252)
14. Gardiner SJ, Bedd EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58:521-590. (Pubitemid 44403684)
15. Sullivan-Klose TH, Ghayarem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-349. (Pubitemid 26288624)
16. Rettie AE, Wienkers LC, González FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42. (Pubitemid 24106122)
17. Higashi MK, Veenstra DL, Kondo LM,Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and coagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698. (Pubitemid 34289221)
18. Schwartz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999-1008. (Pubitemid 351347099)
19. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Öngen Z, et al. Frequency of cytochrome P450 2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48:409-415. (Pubitemid 29417726)
20. Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID ulceration? Br J Clin Pharmacol 2001; 51:627-630. (Pubitemid 32862753)
21. Vonkeman HE, Van de Laar MAFJ, Van der Palen J, Brouwers J, Vermes I. Allele variants of the cytochrome P450 2C9 genotype in white subjects from the Netherlands with serious gastroduodenal ulcers attributable to the use of NSAID. Clin Ther 2006; 28:1670-1676. (Pubitemid 44841985)
22. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133:465-471. (Pubitemid 47193129)
23. Ma J, Yang XY, Qiao L, Liang LQ, Chen MH. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy. J Dig Dis 2008; 9:79-83. (Pubitemid 351566628)
24. Blanco G, Martínez C, Ladero JM, García-Martín E, Taxonera C, Gamito FC, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics 2008; 18:37-43. (Pubitemid 351222384)
25. Carbonell N, Vertuyft C, Massard J, Letierce A, Cellier C, Deforges L, et al. CYP2C9*3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAID other than aspirin. Clin Pharmacol Ther 2010; 87:693-698.
26. Yasar M, Eliasson E, Dahl ML, Johansson I, Ingelman-Sunberg M, Sjovist F. Validation of the methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254:628-631. (Pubitemid 29290517)
27. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289:533-538. (Pubitemid 23042065)
28. Bon MA, Jasen Steur EN, De Vos RA, Vermes I. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism. Neurosci Lett 1999; 266:149-151. (Pubitemid 29227346)
29. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84:775-778.
30. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5:37-42.
31. García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76:119-127. (Pubitemid 39013402)
32. Verstuyft C, Morin S, Yang J, Loriot MA, Barbu V, Kerb R, et al. A new, rapid and robust genotyping method for CYP2C9 and MDR1. Ann Biol Clin 2003; 61:305-309. (Pubitemid 36708676)
33. Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding alter NSAID use. Br J Pharmacol 2004; 141:205-208. (Pubitemid 38250889)
34. Morin S, Bodin L, Loriot MA, Thijssen HHW, Robert A, Strabach S, et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004; 75:403-414. (Pubitemid 38534561)
35. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 2C9 locus. Pharmacogenetics 1996; 6:429-439. (Pubitemid 26380099)
36. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation. Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52:1502-1517.
37. Andrieu N, Goldstein AM. Epidemiologic and genetic approaches in the study of gene-environment interaction: an overview of available methods. Epidemiol Rev 1988; 20:137-147.
38. Albert PS, Ratnasighe D, Tangrea J, Wacholder S. Limitations of the caseonly design for identifying gene-environment interactions. Am J Epidemiol 2001; 154:687-693. (Pubitemid 32971488)
39. Ahlbom A, Alfredsson L. Interaction: a word with two meanings creates confusion. Eur J Epidemiol 2005; 20:563-564. (Pubitemid 41126029)
40. García-Martín E, Martínez C, Ladero JM, Agú ndez JAG. Interethnic and intraethnic variability of CYp2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diag Ther 2006; 10:29-40.
41. Sá nchez-Diz P, Estany-Gestal A, Aguirre C, Blanco A, Carracedo A, Ibáñ ez L, et al. Prevalence of CYP2C9 polymorphisms in the south of Europe. TPJ 2009; 16:1-5.
42. Yang JQ, Morin S, Verstuyff C, Fan LA, Zhang Y, Xu CD, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 2003; 17: 373-376. (Pubitemid 36774173)
43. Weiss ST, Silverman EK, Palmer LJ. Case-control association studies in pharmacogenetics. Pharmacogenomics J 2001; 1:157-158.
44. Van Oijen MG, Laheij RJ. Impact of CYP2C9 genotype on pharmacokinetics: are all NSAID the same? Gastroenterology 2007; 133:2073-2074. (Pubitemid 350180824)
45. Ji KY, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 2006; 12:3789-3792.
46. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a metaanalysis. Lancet 2002; 359:14-22. (Pubitemid 34119190)
47. Shiotani A, Sakakibara T, Nomura M, Yamanaka M, Nishi R, Imamura H, et al. Aspirin-induced ulcer and genetic polymorphisms. J Gastroenterol Hepatol 2010; 25:31-34.
48. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, De Faire U, et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299:25-28. (Pubitemid 35366030)
49. Agú ndez JAG, García-Martín E, Martínez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 2009; 5:1-14.
50. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607. (Pubitemid 32953585)
51. Rodriguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 2008; 8:268-277. (Pubitemid 352038306)
52. Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996; 51:1003-1008.
53. Agúndez JA, Martínez C, García-Martín E, Ladero JM. Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding. Gastroenterology 2007; 133:2071-2072. (Pubitemid 350180821)